Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 04/21 10:01:17 pm
121.76 USD   -0.09%
04/22 JOHNSON & JOHNS : Sun Sentinel Ira Winderman column
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 The DOs and the DON’Ts of a media pitch
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J in $4 Billion Settlement Talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2013 | 11:16pm CEST

Johnson & Johnson (JNJ) has agreed to pay $4 billion to settle more than 7,500 lawsuits over the company's recalled hip-implant products, Bloomberg News reported Tuesday, citing three people familiar with the agreement.

The settlement will be announced next week, Bloomberg reported.

Full story at: www.bloomberg.com/news/2013-11-12/j-j-said-to-reach-4-billion-deal-to-settle-hip- awsuits.html

Write to [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
04/22 JOHNSON & JOHNSON : Sun Sentinel Ira Winderman column
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 The DOs and the DON’Ts of a media pitch
04/20 JOHNSON & JOHNSON : DePuy Synthes Acquires Tissue Regeneration System’s 3D..
04/20 JOHNSON & JOHNSON : Today's Research Reports on Stocks to Watch: Johnson & Johns..
04/20 UNILEVER : David Indo, co-founder of ID Comms, on media pitches, e-auctions and ..
04/19 JOHNSON & JOHNSON : Reports 2017 First Quarter Results
04/19 JOHNSON & JOHNSON : Says Pricing Competition Squeezed 1Q Sales
04/19 JOHNSON & JOHNSON : J&J revenue misses on lower-than-expected pharmaceutical sal..
04/19 JOHNSON & JOHNSON : Agloan-Stocks Fall on Weak Company Earnings
More news
Sector news : Pharmaceuticals - NEC
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
04/19DJFARON PHARMACEUTICALS OY : Appoints Two Non-Executive Directors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:27a 1st Quarter Portfolio Results - Better Than Expected
04/21 FDA approves Merck biosimilar for immune-disorder drug Renflexis
04/21 JOHNSON & JOHNSON : Need Rock-Solid Dividend Growth? Look Here
04/21 DIVIDENDS & INCOME DIGEST : What Are You Doing To Mitigate Risk?
04/21 Keep It 100
Advertisement
Financials ($)
Sales 2017 75 714 M
EBIT 2017 23 390 M
Net income 2017 17 887 M
Debt 2017 6 597 M
Yield 2017 2,76%
P/E ratio 2017 18,57
P/E ratio 2018 16,68
EV / Sales 2017 4,45x
EV / Sales 2018 4,27x
Capitalization 330 078 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 129 $
Spread / Average Target 5,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.88%200 330
NOVARTIS AG-1.15%192 857
MERCK & CO., INC.5.13%169 673
SANOFI8.35%114 121
More Results